Clinical trials: Myelodysplasia
Myelodysplastic Syndrome
The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes
To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes.
- Trial name
- NCT00247026
- Testing
- curcumin; coenzyme q10
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Leukemia, Myelodysplastic Syndrome
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00943800
- Testing
- Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Chicago
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment…
- Trial name
- NCT02085798
- Testing
- Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
- Where
- 50 sites in Spain
- Volunteers
- 503 people
- Sponsor
- Celgene
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma
- Trial name
- NCT00008216
- Testing
- Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Columbia University
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic…
- Trial name
- NCT05209152
- Testing
- AMG 176, Azacitidine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Background: Trisomy 8 mosaicism is a genetic disorder that can increase inflammation in the body. Symptoms include fevers; sores or ulcers in the mouth, digestive tract, or genital area; skin rashes; problems in organs or…
- Conditions
- Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations
- Trial name
- NCT07683104
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia…
- Trial name
- NCT04655755
- Testing
- Decitabine and Cedazuridine, Venetoclax
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003415
- Testing
- amifostine trihydrate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Arizona
Leukemia
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
The goal of this clinical research study is to determine the effectiveness of alemtuzumab in patients with aplastic anemia, MDS, or T-Cell large granular lymphocytic leukemia. The safety of alemtuzumab will also be studied.
- Trial name
- NCT01191749
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Paroxysmal Hemoglobinuria, Nocturnal
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
- Trial name
- NCT00122317
- Testing
- eculizumab
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 187 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myelodysplastic Syndrome
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
- Trial name
- NCT00044382
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Celgene
Leukemia, Myeloid, Acute
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
This is a Phase 1, open label, two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML or HR-MDS.
- Trial name
- NCT05424380
- Testing
- GSK3745417
- Where
- 10 sites in Canada, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Background: Several types of blood cancer are associated with poor outcomes including high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myelogenous leukemia (AML).
- Conditions
- Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, Bone Marrow Diseases, Neutropenia
- Trial name
- NCT01629082
- Testing
- Clofarabine, Lenalidomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases.
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT06013423
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoid, Leukemia, Myeloid
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant.
- Conditions
- Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes, Myelofibrosis
- Trial name
- FluBuATG (NCT02916979)
- Testing
- Fludarabine, Busulfan, Rabbit ATG
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Neoplasms, Solid Tumor, Adult
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended…
- Conditions
- Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT03573310
- Testing
- JNJ-64619178
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 114 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
This is a single center, "modified standard design" dose escalation study designed to determine the maximum tolerated, minimum efficacious dose (MTD/MED) of IL-15 (Intravenous Recombinant Human IL-15) and incidence of donor…
- Trial name
- NCT01385423
- Testing
- Preparative Regimen, Intravenous Recombinant Human IL-15 (rhIL-15)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal…
- Conditions
- Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
- Trial name
- NCT06412497
- Testing
- Rituximab, Rabbit ATG, Cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelodysplastic Syndrome
The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome
The purpose of this study is determine whether combination Q10 , L-carnitine and multivitamin and mineral complex is effective in treatment of patients with low and intermidiate1-2 risk Myelodysplastic syndrome
- Trial name
- NCT02042482
- Testing
- Coenzyme Q10U, L-carnitine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Kaplan Medical Center
Myelodysplastic Syndrome
Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?
Researchers from Memorial Sloan-Kettering Cancer Center, in collaboration with The New York Presbyterian Hospital-Weill Medical College of Cornell University, are conducting a study of a medicinal mushroom extract called Maitake…
- Trial name
- NCT01099917
- Testing
- Maitake
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.